Turn Therapeutics Registers 25.4M Shares for Resale Under $85M GEM Equity Line
TTRX has more than doubled off its 52-week low of $2.57.
Summary
Turn Therapeutics registered up to 25,362,950 shares for resale under its $85.0M GEM equity line — about 83% of shares outstanding — and disclosed it has already drawn roughly $4.07M plus a second ~$2.72M draw-down.
Key Events · Financing and Capital Events · TTRX
-
25.4M Shares Registered for Resale
Selling stockholders may resell up to 25,362,950 shares, about 82.96% of the 30,572,704 shares outstanding as of November 6, 2026.
-
GEM Equity Line Terms Quantified
GEM committed up to $85.0M, buying at 90% of the 15-day average closing price with a $1.00 floor; draw-downs are capped at 300% of average daily volume and GEM at 9.99% ownership.
-
Draw-Downs Already Underway
1,235,200 shares sold to GEM for about $4.07M at roughly $3.29 per share, and a second notice on October 29, 2026 for 272,642 shares with about $2.72M advanced; roughly $75.0M remains available.
-
Company Gets No Resale Proceeds
Turn receives nothing from selling-stockholder sales; cash comes only from new share sales to GEM, earmarked for working capital and general corporate purposes.
Analysis · TTRX · Life Sciences
The GEM committed equity line becomes tradable with this prospectus: selling stockholders may resell up to 25,362,950 shares — roughly 83% of the 30.57M shares outstanding — while the company can draw up to $85.0M from GEM at 90% of the 15-day average price, subject to a $1.00 floor. That is a persistent dilution overhang rather than a one-time raise, and it matters most because the company is burning cash with a going-concern warning and only $10.4M of cash. Already the line is in use: 1,235,200 shares sold for about $4.07M at roughly $3.29 each, plus a second draw-down for 272,642 shares with about $2.72M advanced on October 29, 2026. Resales generate no proceeds for the company; cash arrives only when it elects to sell new shares to GEM.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TTRX was trading at $8.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $261.4M. The 52-week trading range was $2.57 to $16.45. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.